Gender is an important determinant of the disposition of the loop diuretic torasemide

Journal of Clinical Pharmacology

Volumn 50, Issue 2, 2010, Pages 160-168

  Werner, Ulrike ^a   Werner, Dierk ^b   Heinbüchner, Svetlana ^b   Graf, Bernhard ^b   Ince, Hüseyin ^c   Kische, Stefan ^d   Thürmann, Petra ^e   König, Jörg ^f   Fromm, Martin F ^f   Zolk, Oliver ^f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Cardiology   (Germany)

^c Department of Cardiology   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Gender; Loop diuretics; OATP1B1; Torasemide

Indexed keywords

CYTOCHROME P450 2C9; MEMBRANE PROTEIN; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 4; TORASEMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; GENE FREQUENCY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CELL LINE; DIURETICS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MUTAGENESIS, SITE-DIRECTED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; SEX FACTORS; SULFONAMIDES;

EID: 75749107064     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337514     Document Type: Article

References (28)

1. Zopf Y., Rabe C., Neubert A., et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008 ; 64: 999-1004.
2. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998 ; 46: 505-511.
3. Rademaker M. Do women have more adverse drug reactions ? Am J Clin Dermatol. 2001 ; 2: 349-351.
4. Thürmann PA, Hompesch BC Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther. 1998 ; 36: 586-590.
5. Thürmann PA Sex-specific differences in drug treatment. Ther Umsch. 2007 ; 64: 325-329.
6. Kaiser J. Gender in the pharmacy: does it matter ? Science. 2005 ; 308: 1572.
7. Thürmann PA, Werner U., Hanke F., et al. Arzneimittelrisiken bei hochbetagten Patienten: Ergebnisse deutscher Studien. Fortschritt und Fortbildung in der Medizin. 2008 ; 31: 216-224.
8. Werner U., Szymanski J., Schmiedl S., et al. Women suffer more frequently from serious adverse drug reactions caused by diuretics: results from the German pharmacovigilance centres 2000-2006. Basic Clin Pharmacol Toxicol. 2008.
9. Werner D., Werner U., Meybaum A., et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet. 2008 ; 47: 323-332.
10. Miners JO, Rees DL, Valente L., Veronese ME, Birkett DJ Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther. 1995 ; 272: 1076-1081.
11. Miners JO, Coulter S., Birkett DJ, Goldstein JA Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics. 2000 ; 10: 267-270.
12. Vormfelde SV, Engelhardt S., Zirk A., et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther. 2004 ; 76: 557-566.
13. Vormfelde SV, Schirmer M., Toliat MR, et al. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J. 2007 ; 7: 200-211.
14. Vormfelde SV, Toliat MR, Schirmer M., Meineke I., Nürnberg P., Brockmöller J. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008 ; 83: 815-817.
15. Vormfelde SV, Schirmer M., Hagos Y., et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol. 2006 ; 62: 323-335.
16. Cui Y., König J., Buchholz JK, Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 ; 55: 929-937.
17. Oswald S., König J., Lutjohann D., et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008 ; 18: 559-568.
18. Treiber A., Schneiter R., Hausler S., Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 ; 35: 1400-1407.
19. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 ; 34: 1229-1236.
20. Bachmakov I., Glaeser H., Fromm MF, König J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 ; 57: 1463-1469.
21. Cerrutti JA, Quaglia NB, Brandoni A., Torres AM Effects of gender on the pharmacokinetics of drugs secreted by the renal organic anions transport systems in the rat. Pharmacol Res. 2002 ; 45: 107-112.
22. Brandoni A., Villar SR, Torres AM Gender-related differences in the pharmacodynamics of furosemide in rats. Pharmacology. 2004 ; 70: 107-112.
23. Kling L., Schaumann W., Kaufmann B., Sponer G., Bartsch W. Sex difference in saluretic and diuretic activity of torasemide in Sprague-Dawley rats. Naunyn-Schmiedbergs Arch Pharmacol. 1991 ; 344: R114.
24. König J., Seithel A., Gradhand U., Fromm MF Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 372: 432-443.
25. Seithel A., Glaeser H., Fromm MF, König J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol. 2008 ; 4: 51-64.
26. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008 ; 359: 789-799.
27. Tirona RG, Leake BF, Wolkoff AW, Kim RB Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 ; 304: 223-228.
28. Nozawa T., Nakajima M., Tamai I., et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002 ; 302: 804-813.